"Immunization, Secondary" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Any immunization following a primary immunization and involving exposure to the same or a closely related antigen.
| Descriptor ID |
D007117
|
| MeSH Number(s) |
E02.095.465.425.400.485 E05.478.550.550
|
| Concept/Terms |
Immunization, Secondary- Immunization, Secondary
- Immunizations, Secondary
- Secondary Immunizations
- Immunization, Booster
- Booster Immunization
- Booster Immunizations
- Immunizations, Booster
- Secondary Immunization
|
Below are MeSH descriptors whose meaning is more general than "Immunization, Secondary".
Below are MeSH descriptors whose meaning is more specific than "Immunization, Secondary".
This graph shows the total number of publications written about "Immunization, Secondary" by people in this website by year, and whether "Immunization, Secondary" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 |
| 1995 | 2 | 0 | 2 |
| 1996 | 0 | 2 | 2 |
| 1997 | 1 | 1 | 2 |
| 1998 | 0 | 2 | 2 |
| 1999 | 0 | 3 | 3 |
| 2000 | 1 | 0 | 1 |
| 2002 | 0 | 2 | 2 |
| 2004 | 1 | 1 | 2 |
| 2005 | 0 | 2 | 2 |
| 2006 | 0 | 3 | 3 |
| 2007 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2009 | 2 | 2 | 4 |
| 2010 | 3 | 3 | 6 |
| 2011 | 0 | 2 | 2 |
| 2013 | 1 | 1 | 2 |
| 2014 | 1 | 2 | 3 |
| 2015 | 2 | 1 | 3 |
| 2016 | 1 | 1 | 2 |
| 2017 | 0 | 1 | 1 |
| 2019 | 1 | 2 | 3 |
| 2021 | 1 | 3 | 4 |
| 2022 | 2 | 5 | 7 |
| 2023 | 1 | 2 | 3 |
| 2024 | 7 | 0 | 7 |
To return to the timeline,
click here.
Below are the most recent publications written about "Immunization, Secondary" by people in Profiles.
-
SARS-CoV-2 XBB.1.5 mRNA booster vaccination elicits limited mucosal immunity. Sci Transl Med. 2024 Oct 23; 16(770):eadp8920.
-
Determination of T cell response against XBB variants in adults who received either monovalent wild-type inactivated whole virus or mRNA vaccine or bivalent WT/BA.4-5 COVID-19 mRNA vaccine as the additional booster. Int J Infect Dis. 2024 Dec; 149:107271.
-
Omicron COVID-19 immune correlates analysis of a third dose of mRNA-1273 in the COVE trial. Nat Commun. 2024 Sep 11; 15(1):7954.
-
Long-term safety and effectiveness of mRNA-1273 vaccine in adults: COVE trial open-label and booster phases. Nat Commun. 2024 Aug 29; 15(1):7469.
-
Robust SARS-CoV-2-neutralizing antibodies sustained through 6?months post XBB.1.5 mRNA vaccine booster. Cell Rep Med. 2024 Sep 17; 5(9):101701.
-
A Phase 2 Clinical Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of Different Prime-Boost Vaccination Schedules of 2013 and 2017 A(H7N9) Inactivated Influenza Virus Vaccines Administered With and Without AS03 Adjuvant in Healthy US Adults. Clin Infect Dis. 2024 Jun 14; 78(6):1757-1768.
-
Imprinting of serum neutralizing antibodies by Wuhan-1 mRNA vaccines. Nature. 2024 Jun; 630(8018):950-960.
-
Refractory chronic spontaneous urticaria after heterologous COVID-19 booster vaccination. Dermatol Online J. 2024 Apr 15; 30(2).
-
Mucosal boosting enhances vaccine protection against SARS-CoV-2 in macaques. Nature. 2024 Feb; 626(7998):385-391.
-
Neutralization escape by SARS-CoV-2 Omicron subvariant BA.2.86. Vaccine. 2023 11 13; 41(47):6904-6909.